174 related articles for article (PubMed ID: 946155)
1. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy.
Harper ME; Peeling WB; Cowley T; Brownsey BG; Phillips ME; Groom G; Fahmy DR; Griffiths K
Acta Endocrinol (Copenh); 1976 Feb; 81(2):409-26. PubMed ID: 946155
[TBL] [Abstract][Full Text] [Related]
2. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men.
Wiegelmann W; Solbach HG; Kley HK; Nieschlag E; Rudorff KH; Krüskemper HL
Horm Res; 1976; 7(1):1-10. PubMed ID: 793974
[TBL] [Abstract][Full Text] [Related]
3. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
Usuki S; Kondoh K; Kubo T
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
[TBL] [Abstract][Full Text] [Related]
4. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
Bishop MC; Selby C; Taylor M
Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
[TBL] [Abstract][Full Text] [Related]
5. The effects of chlorotrianisene (Tace) of kinetics of 3H-testosterone metabolism in patients with carcinoma of the prostate.
Baba S; Janetschek G; Pollow K; Hahn K; Jacobi GH
Br J Urol; 1982 Aug; 54(4):393-8. PubMed ID: 6810984
[TBL] [Abstract][Full Text] [Related]
6. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens.
Boyns AR; Cole EN; Phillips ME; Hillier SG; Cameron EH; Griffiths K; Shahmanesh M; Feneley RC; Hartog M
Eur J Cancer (1965); 1974 Jul; 10(7):445-9. PubMed ID: 4376085
[No Abstract] [Full Text] [Related]
7. Testosterone metabolism in patients with advanced carcinoma of the prostate: a comparative in vivo study of the effects of oestrogen and antiprolactin.
Jacobi GH; Sinterhauf K; Kurth KH; Altwein JE
Urol Res; 1978; 6(3):159-65. PubMed ID: 758043
[TBL] [Abstract][Full Text] [Related]
8. Some effects of treatment with ethinyl oestradiol with or without polyoestradiol phosphate in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol; 1986; 20(3):193-6. PubMed ID: 3097813
[TBL] [Abstract][Full Text] [Related]
9. Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men.
Ortega E; Ruiz E; Mendoza MC; Martin-Andres A; Osorio C
Experientia; 1979 Jun; 35(6):844-5. PubMed ID: 89045
[TBL] [Abstract][Full Text] [Related]
10. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade.
Harper ME; Wilson DW; Jensen HM; Pierrepoint CG; Griffiths K
J Steroid Biochem; 1987; 27(1-3):521-4. PubMed ID: 3121925
[TBL] [Abstract][Full Text] [Related]
12. A study of the endocrine manifestations of hepatic cirrhosis.
Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
[TBL] [Abstract][Full Text] [Related]
13. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
Siegberg R; Nilsson CG; Stenman UH; Widholm O
Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
[TBL] [Abstract][Full Text] [Related]
14. Influence of orchidectomy or oestrogen treatment on serum levels of pregnancy associated alpha 2-glycoprotein and sex hormone binding globulin in patients with prostatic cancer.
Carlström K; Eriksson A; Gustafsson SA; Henriksson P; Pousette A; Stege R; von Schoultz B
Int J Androl; 1985 Feb; 8(1):21-7. PubMed ID: 3922901
[TBL] [Abstract][Full Text] [Related]
15. Testicular endocrine function after withdrawal of oestrogen treatment in patients with carcinoma of the prostate.
Tomić R; Bergman B; Damber JE
Br J Urol; 1983 Feb; 55(1):42-7. PubMed ID: 6402048
[TBL] [Abstract][Full Text] [Related]
16. Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 beta-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia.
Stahl F; Schnorr D; Rohde W; Poppe I; Geier T; Dörner G
Exp Clin Endocrinol; 1983 Jul; 82(1):21-8. PubMed ID: 6193975
[TBL] [Abstract][Full Text] [Related]
17. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.
Andersson SO; Adami HO; Bergström R; Wide L
Br J Cancer; 1993 Jul; 68(1):97-102. PubMed ID: 8318428
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. British Prostate Study Group.
Br J Urol; 1979 Oct; 51(5):382-9. PubMed ID: 533596
[TBL] [Abstract][Full Text] [Related]
19. Climacteric symptoms, fat mass, and plasma concentrations of LH, FSH, Prl, oestradiol-17 beta and androstenedione in the early post-menopausal period.
Hagen C; Christiansen C; Christensen MS; Transbøl I
Acta Endocrinol (Copenh); 1982 Sep; 101(1):87-92. PubMed ID: 6812347
[No Abstract] [Full Text] [Related]
20. Carcinoma of the prostate: relationship of pretreatment hormone levels to survival.
Harper ME; Pierrepoint CG; Griffiths K
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):477-82. PubMed ID: 6426967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
